BSE filing, NSE: IIFLCAPS. Summary written from the filing by ALFA Finder's alert engine.
IIFL Capital Services Ltd: key numbers
- Share price
- ₹346.00
- Market cap
- ₹10,911 Cr
- Revenue (annual)
- ₹2,420 Cr
- Net profit (annual)
- ₹561.4 Cr
- P/E (TTM)
- 19.1×Sector 19.7×
- Promoter holding
- 30.49%-0.18% QoQ
- FII holding
- 15.37%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from IIFL Capital Services Ltd
All →IIFL Capital Services Adverse Business Impact
IIFL Capital Services' subsidiary surrendered its SEBI Investment Adviser registration, effective October 28, 2026. The company states there is no material monetary impact and no penalty.
IIFL Capital Services Results Update
IIFL Capital Services reported consolidated Q2FY27 revenue of ₹722 crore, up 22% year-on-year, with PBT of ₹174 crore. The press release also covers the Fairfax change-in-control and a proposed NBFC subsidiary.
IIFL Capital Services Investor Presentation: Key Takeaways
Q2FY27 revenue ₹7,219 Mn (+22% YoY) and PAT ₹1,266 Mn (+49% YoY). H1FY27 PAT ₹3,108 Mn (+19%). Fairfax to acquire up to 51% with ~₹20 bn capital infusion.
IIFL Capital Services Management Change
IIFL Capital's board appointed Vasudev Jagannath as Additional and Whole-Time Director. He will become Managing Director from January 2027, subject to approvals.
- Execution
- 3 years from appointment
IIFL Capital Services Q2 FY27 Results: Net Profit ₹126.6 Cr, Up 48.8% YoY
IIFL Capital Services Ltd reported revenue from operations of ₹714.4 Cr (+24.9% YoY) and net profit of ₹126.6 Cr (+48.8% YoY) for Q2 FY27.
- Key figure
- Net profit ₹126.6 Cr · +48.8% YoY
IIFL Capital Services Board Meeting Date
IIFL Capital Services will hold a board meeting on 28 October 2026 to consider unaudited standalone and consolidated results for the quarter and half year ended September 30, 2026. The trading window stays closed from 01 to 30 October 2026.
Other other announcement announcements
All →Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Sagarsoft (India) Other Announcement
Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.
Sadhana Nitro Chem Other Announcement
Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.
Shriram Asset Management Company Other Announcement
Shriram AMC filed ICRA's quarterly monitoring agency report on preferential issue proceeds. Utilisation is in line with the offer objects, with no deviation reported.
Jhandewalas Foods Other Announcement
Jhandewalas Foods filed its quarterly shareholding pattern for the period ended September 30, 2026. The filing records holdings by category and contains no transaction or money event.
Avience Biomedicals Other Announcement
Avience Biomedicals confirmed corporate governance compliance is not applicable, as it is SME-listed on NSE Emerge. No quarterly governance report is required for September 2026.